Zinger Key Points
- Alzamend completed a head coil to enable precise brain imaging of lithium in upcoming Phase 2 trials.
- Nonclinical data show AL001 improves brain absorption with lower blood levels than lithium carbonate, suggesting better safety and efficacy.
- Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden opportunities in the post-earnings chaos.
On Wednesday, Alzamend Neuro, Inc. ALZN announced it had completed the head coil by Tesla Dynamic Coils BV.
The development of the head coil was necessary to facilitate Alzamend's five upcoming Phase 2 clinical trials.
In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend intends to undertake clinical trials to assess how lithium levels in the brain differ when using AL001 compared to marketed lithium salts, both in healthy individuals and patients with Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
The engineered head coil will enable whole-brain imaging of lithium with remarkable resolution, allowing precise quantification within brain structures.
The coil will be used to help identify the disease-specific target doses of AL001 that improve the balance of safety and efficacy compared to lithium carbonate.
The coil will also be used to scan the entire brain, helping to identify the different structures and important areas necessary for understanding how lithium works and moves within the brain.
Nonclinical (mouse) studies have already demonstrated that AL001 optimizes brain absorption with lower blood concentration levels than lithium carbonate.
In November, Alzamend Neuro finished analyzing the final full data set from a nonclinical study comparing brain and plasma lithium exposures between AL001 and lithium carbonate in Alzheimer's transgenic mice.
Mice received high or low doses scaled to humans of AL001 and lithium carbonate over 14 days to observe pharmacokinetic steady-state drug conditions.
The company said that the results highlight the potential clinical advantages of AL001 for conditions like Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder at low doses.
Price Action: ALZN stock was down by 7.41% to $1.00 during the premarket session at the last check on Wednesday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
